LUNGevity Foundation, the nation’s leading lung cancer-focused nonprofit organization, has created a new resource: Lung Cancer Patient Gateways. The first to launch is the KRAS Patient Gateway, which will allow patients with cancer and the KRAS gene mutation to more easily locate resources and treatment information as well as to find a community of patients and caregivers.
“There have been substantial, even extraordinary, advances in scientific lung cancer research over the past decade,” said Andrea Ferris, President and Chief Executive Officer of LUNGevity Foundation. “With such rapidly advancing science and resulting treatment options, both newly diagnosed patients and their physicians stand to benefit from having an interactive resource where the latest information about the disease is readily available. We’re grateful to Amgen for providing the funding for the KRAS Gateway website.”
Andrea Ferris
The KRAS Patient Gateway is a user-friendly and easily accessible information portal that offers the latest medical updates and potentially life-saving resources for people living with KRAS markers for lung cancer. The Gateway, available at kras.lungevity.org, will provide a single comprehensive place for people living with lung cancer to learn about KRAS; find a specialist based on individualized search criteria; join a variety of KRAS communities; explore clinical trial options; and read up-to-the-minute, curated news and trends.
Six Platforms
The KRAS Patient Gateway is just the first of six platforms that will be released over the next 6 months at gateway.lungevity.org. The other five will be aimed at different types of lung cancer including non–small cell and small cell lung cancer, as well as specific mutations responsible for initiating and supporting lung cancer growth, such as ALK; EGFR; and other rare mutations such as ROS1, MET, NTRK, BRAF, RET, and more.
LUNGevity Foundation is the nation’s leading lung cancer organization focused on improving outcomes for people with lung cancer through research, education, policy initiatives, and support and engagement for patients, survivors, and caregivers.
